Business models and opportunities for cancer vaccine developers

Kudrin, Alex

doi:10.4161/hv.20629

Cited by 4 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…– Network of separate entities (universities, hospitals, technology suppliers, contract research organisations and manufacturing, data analysis firms and key opinion leaders from numerous countries; independent research sites) [ 46 , 56 ]…”

Section: Resultsmentioning

confidence: 99%

“…Partnerships between funding organisations, academic institutions, and pharmaceutical companies were described as having the potential to facilitate funding streams and collaborations by providing support and access to non-marketed compounds [ 31 ] (Table 3 ). It was also noted that virtual and venture variants of partnerships could facilitate the financing of new business areas by spreading the capital initially required, and enabling strategic outsourcing and investment instead of costly mergers and acquisitions [ 46 ]. It was proposed that “Open source innovation” [ 39 , 56 ]—the exchange of internal and external ideas and knowledge to advance technology—could replace the traditional in-house-focused approach and incentivise new collaborations [ 39 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Koleva-Kolarova

Buchanan

Vellekoop

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background The number of healthcare interventions described as ‘personalised medicine’ (PM) is increasing rapidly. As healthcare systems struggle to decide whether to fund PM innovations, it is unclear what models for financing and reimbursement are appropriate to apply in this context. Objective To review financing and reimbursement models for PM, summarise their key characteristics, and describe whether they can influence the development and uptake of PM. Methods A literature review was conducted in Medline, Embase, Web of Science, and Econlit to identify studies published in English between 2009 and 2021, and reviews published before 2009. Grey literature was identified through Google Scholar, Google and subject-specific webpages. Articles that described financing and reimbursement of PM, and financing of non-PM were included. Data were extracted and synthesised narratively to report on the models, as well as facilitators, incentives, barriers and disincentives that could influence PM development and uptake. Results One hundred and fifty-three papers were included. Research and development of PM was financed through both public and private sources and reimbursed largely through traditional models such as single fees, Diagnosis-Related Groups, and bundled payments. Financial-based reimbursement, including rebates and price-volume agreements, was mainly applied to targeted therapies. Performance-based reimbursement was identified mainly for gene and targeted therapies, and some companion diagnostics. Gene therapy manufacturers offered outcome-based rebates for treatment failure for interventions including Luxturna ® , Kymriah ® , Yescarta ® , Zynteglo ®, Zolgensma ® and Strimvelis ® , and coverage with evidence development for Kymriah ® and Yescarta ® . Targeted testing with OncotypeDX ® was granted value-based reimbursement through initial coverage with evidence development. The main barriers and disincentives to PM financing and reimbursement were the lack of strong links between stakeholders and the lack of demonstrable benefit and value of PM. Conclusions Public-private financing agreements and performance-based reimbursement models could help facilitate the development and uptake of PM interventions with proven clinical benefit. Supplementary Information The online version contains supplementary material available at 10.1007/s40258-021-00714-9.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Koleva-Kolarova

Buchanan

Vellekoop

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

show abstract

“…However, EvaluatePharma reported consensus analyst forecasts of $45 million and $250 million for worldwide Imlygic sales in 2016 and 2022, respectively ( Imlygic, 2017 ). Financial reports in 2012 revealed that over 6000 patients diagnosed with various types of solid cancers in China received Gendicin, which had a CAGR from 2004 to 2011 of 68.3% ( Kudrin, 2018 ). Sales of Gendicin were $3.6 million in 2007 and $16 million in 2008.…”

Section: Market Size Of Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

“…Sales of Gendicin were $3.6 million in 2007 and $16 million in 2008. However, the sales of Oncorine were unsatisfactory in China (<$1.2) due to its high price in 2009 ( Kudrin, 2018 ). Products indicted for immunological disorders show that Alofisel is forecasted by Evaluate Pharma that the worldwide consensus sales will reach $529 million in 2024 ( Mesoblast Limited, 2020 ).…”

Section: Market Size Of Advanced Therapy Medicinal Products (Atmps)mentioning

confidence: 99%

Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies

Ramezankhani

Torabi

Minaei

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The introduction of advanced therapy medicinal products (ATMPs) to the global pharma market has been revolutionizing the pharmaceutical industry and has opened new routes for treating various types of cancers and incurable diseases. In the past two decades, a noticeable part of clinical practices has been devoting progressively to these products. The first step to develop such an ATMP product is to be familiar with other approved products to obtain a general view about this industry trend. The present paper depicts an overall perspective of approved ATMPs in different countries, while reflecting the degree of their success in a clinical point of view and highlighting their main safety issues and also related market size as a whole. In this regard, published articles regarding safety, efficacy, and market size of approved ATMPs were reviewed using the search engines PubMed, Scopus, and Google Scholar. For some products which the related papers were not available, data on the relevant company website were referenced. In this descriptive study, we have introduced and classified approved cell, gene, and tissue engineering-based products by different regulatory agencies, along with their characteristics, manufacturer, indication, approval date, related regulatory agency, dosage, product description, price and published data about their safety and efficacy. In addition, to gain insights about the commercial situation of each product, we have gathered accessible sale reports and market size information that pertain to some of these products.

show abstract

“…The qualified management team, the strong position in intellectual property and access to financial resources, the predictability to access skills required in different stages, as well as long-term forecasts under uncertainty conditions are other important features of today's companies in this field. The emphasis of new business models to attract more cooperation, networking and unification methods to achieve corporate goals has been the focus of some researchers [35]. Despite the budgeting difficulties, domination of small and medium-sized enterprises can lead to opportunities to innovate and reduce the dependence on large enterprises and can promote cooperation with universities.…”

Section: The Business Model and Some Operational Characteristicsmentioning

confidence: 99%

Challenge-based approaches for policy-making in vaccine development and production

Marandi

Tabatabaeian

Jafari

et al. 2018

vacres

View full text Add to dashboard Cite

Presently, vaccines development and production has gained more importance due to their influence on topics such as the society's health system and economy, as well as the bio-security issues and the defense affairs. Moreover, the potential innovation capabilities in vaccine production are assumed as engines of biotechnology development which is among the emerging technologies that can support the technological development of a country. This review is based on analyses of scientific articles, literature, textbooks and reports by the international organization, as well as online databases with the subject of innovation in vaccine production, in order to identify current challenges in vaccine development and production. Not long ago, the most important challenges in this field were assumed as technical or budgetary issues. However nowadays, due to a global paradigm-shift in vaccine production which has changed from innovation aimed solely at the registration of new products toward promoting public health, other challenges in competition and commercialization have stepped in. The identified new challenges and bottlenecks could be used to form practical approaches in policy-making toward vaccine development and production. Furthermore, overcoming these challenges requires identifying the bottlenecks and proper orientation with the current world circumstances to draft a functional policy that could fulfill the national health system objectives. Here, following explaining these global challenges and approaches, the situation of vaccine industry in Iran will be briefly discussed.

show abstract

Business models and opportunities for cancer vaccine developers

Cited by 4 publications

References 7 publications

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options

Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies

Challenge-based approaches for policy-making in vaccine development and production

Contact Info

Product

Resources

About